Thus, PD-1/PD-L1 like LAG-3 inhibition acts directly at the tumor site, whereas CTLA-4 inhibition acts mainly during T cell priming when antigen-presenting cells (APC) and the T cells interact in lymph nodes. Here, CTLA4 is linked to neoplasm.